Gain Therapeutics shares surge 22.22% premarket after Phase 1b data show first-ever GluSph reduction in CSF.

Gain Therapeutics (GANX) surged 22.22% in premarket trading following the release of Phase 1b clinical data showing a first-ever reduction in cerebrospinal fluid (CSF) glucosylsphingosine (GluSph) levels in Parkinson’s disease (PD) patients after 90 days of GT-02287 treatment. The prespecified exploratory endpoint demonstrated central nervous system (CNS) target engagement and increased GCase activity, suggesting the drug may slow PD progression. The study reported 79% of participants entered a nine-month extension, with the drug generally well-tolerated and a data monitoring committee recommending continued trials. Upcoming key opinion leader (KOL) events in early January further amplified investor optimism by positioning the results for expert validation. These developments highlight GT-02287’s potential as a disease-modifying therapy, driving immediate market confidence in Gain’s Parkinson’s pipeline.